Affimed N.V.
affimed.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 20-F, filed Mar 28, 2024. Its latest SEC filing is a 25-NSE from Jul 21, 2025.
20-F for FY2023, filed Mar 28, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Developed clinical-stage antibody drug candidates designed to bring innate immune cells close to cancer cells, for cancer patients.
20-F for FY2023, filed Mar 28, 2024
Did Revenues Turn Into Profits?
No. It lost EUR 105.9M in .
20-F for FY2023, filed Mar 28, 2024
20-F for FY2023, filed Mar 28, 2024
−EUR 105.9MView ↗
How Were They Changing?
AbCheck sale
The older report described AbCheck as an antibody-screening company serving Affimed and outside drugmakers; the latest report said Affimed had agreed to sell it.
20-F for FY2020, filed Apr 15, 2021 20-F for FY2023, filed Mar 28, 2024In 2009, we formed AbCheck s.r.o., our 100% owned, independently run antibody screening platform company, located in the Czech Republic.…View ↗
In 2009, we formed AbCheck s.r.o. (“AbCheck”), our previously 100% owned, independently run antibody screening platform company, located in…View ↗
Who Did They Compete With?
Competes with Dragonfly Therapeutics, GT Biopharma, and Innate Pharma
20-F for FY2023, filed Mar 28, 2024We expect that our ROCK® platform as well as our novel antibody formats derived from this platform will serve as the basis for future…View ↗
Loading...
